Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 藥學系(所) > 期刊論文 > Item 310902800/34677

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34677

標題:	Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients
作者:	Chen, Tzu-Ju Hsu, Bei-Hao Lee, Sung-Wei Yang, Ching-Chieh Tian, Yu-Feng Kuo, Yu-Hsuan Li, Wan-Shan Tsai, Hsin-Hwa Wu, Li-Ching Yeh, Cheng-Fa Chou, Chia-Lin Lai, Hong-Yue
貢獻者:	Chi Mei Hospital Chung Hua University Chung Shan Medical University Chung Shan Medical University Hospital Department of Pharmacy, Chia Nan University of Pharmacy & Science Chia Nan University of Pharmacy & Science National Sun Yat Sen University Chi Mei Hospital China Medical University Taiwan China Medical University Hospital - Taiwan Chia Nan University of Pharmacy & Science
關鍵字:	keratan sulfate expression glycosaminoglycan differentiation muc2
日期:	2022
上傳時間:	2023-12-11 14:04:41 (UTC+8)
出版者:	FRONTIERS MEDIA SA
摘要:	Objective: To reduce the risk of locoregional recurrence, the addition of neoadjuvant concurrent chemoradiotherapy (CCRT) is recommended before surgical management for rectal cancer patients. However, despite identical tumor histology, individual patient response to neoadjuvant CCRT varies greatly. Accordingly, a comprehensive molecular characterization that is used to predict CCRT efficacy is instantly needed.Methods: Pearson's chi-squared test was utilized to correlate dehydrogenase/reductase 9 (DHRS9) expression with clinicopathological features. Survival curves were created applying the Kaplan-Meier method, and the log-rank test was conducted to compare prognostic utility between high and low DHRS9 expression groups. Multivariate Cox proportional hazards regression analysis was applied to identify independent prognostic biomarkers based on variables with prognostic utility at the univariate level.Results: Utilizing a public transcriptome dataset, we identified that the DHRS9 gene is the most considerably upregulated gene related to epithelial cell differentiation (GO: 0030855) among rectal cancer patients with CCRT resistance. Employing immunohistochemical staining, we also demonstrated that high DHRS9 immunoexpression is considerably associated with an aggressive clinical course and CCRT resistance in our rectal cancer cohort. Among all variables with prognostic utility at the univariate level, only high DHRS9 immunoexpression was independently unfavorably prognostic of all three endpoints (all p <= 0.048) in the multivariate analysis. In addition, applying bioinformatic analysis, we also linked DHRS9 with unrevealed functions, such as keratan sulfate and mucin synthesis which may be implicated in CCRT resistance.Conclusion: Altogether, DHRS9 expression may serve as a helpful predictive and prognostic biomarker and assist decision-making for rectal cancer patients who underwent neoadjuvant CCRT.
關聯:	PATHOLOGY & ONCOLOGY RESEARCH, v.28, Article 1610537
显示于类别:	[藥學系(所)] 期刊論文 [化妝品應用與管理系(所)] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	240	检视/开启
pore.2022.1610537.pdf		1683Kb	Adobe PDF	61	检视/开启

在CNU IR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....